ArticleAdvances in therapy2026
Postoperative Complications Associated with Advanced Therapies in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWhether preoperative advanced therapy increases postoperative complications in inflammatory bowel disease (IBD) is contested. We conducted a cross-class systematic review distinguishing crude from confounding-adjusted estimates.
methodsFive databases were searched to May 2026 for studies of patients with IBD undergoing abdominal surgery. Random-effects meta-analysis estimated comparative odds ratios (ORs) with 95% confidence intervals (CIs) versus unexposed patients across 13 pre-specified outcomes. Confounding-adjusted estimates were pooled separately by inverse-variance, contrasted with crude, meta-regressed on adjustment quality, and rated by GRADE.
resultsNinety-four publications were included. Across the pooled comparisons, advanced therapies were not associated with a uniform excess of postoperative complications; an isolated deep vein thrombosis signal (OR 2.62) most plausibly reflects disease-severity confounding. Crude anti-tumour necrosis factor (anti-TNF) exposure was associated with higher overall complications (OR 1.14, 95% CI 1.02-1.28) and, most reproducibly, intra-abdominal abscess (1.18, 1.01-1.39; 1.34 good-quality); infliximab with sepsis (2.38, 1.30-4.38). Infectious complications, SSI and anastomotic leak were non-significant, and signals were confined to Crohn's disease. After confounding adjustment, anti-TNF odds remained elevated (overall 1.53, 1.12-2.08, k = 18; infectious 1.51, 1.18-1.92) but were heterogeneous, attenuated with adjustment depth to non-significance in the most-adjusted stratum, and null in the only study confirming exposure by measured serum drug levels rather than a preoperative calendar window (infection 1.05). Vedolizumab showed no complication increase but higher readmission (1.70) and reoperation (1.65), consistent with channelling bias.
conclusionsAlthough there was a signal for association of advanced-therapy with certain complications, the signal is small, heterogeneous, of very low certainty, and absent in drug-level-confirmed evidence. These data are not robust evidence of independent harm and do not justify routine preoperative discontinuation or delay of necessary surgery.
trial registrationThis systematic review was prospectively registered with the International Prospective Register of Systematic Reviews (PROSPERO; CRD420261323118).
Indexed as
Identifiers
42606796What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.